Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

OBJECTIVE: We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens....

Descripción completa

Detalles Bibliográficos
Autores principales: Shiha, Gamal, Esmat, Gamal, Hassany, Mohamed, Soliman, Reham, Elbasiony, Mohamed, Fouad, Rabab, Elsharkawy, Aisha, Hammad, Radi, Abdel-Razek, Wael, Zakareya, Talaat, Kersey, Kathryn, Massetto, Benedetta, Osinusi, Anu, Lu, Sophia, Brainard, Diana M, McHutchison, John G, Waked, Imam, Doss, Wahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580781/
https://www.ncbi.nlm.nih.gov/pubmed/29666174
http://dx.doi.org/10.1136/gutjnl-2017-315906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580781/
https://www.ncbi.nlm.nih.gov/pubmed/29666174
http://dx.doi.org/10.1136/gutjnl-2017-315906

Ejemplares similares